|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, a multivariate logistic regression model showed that neither MICA(*)009 nor the combination MICA(*)009/HLA-B(*)51 was associated with melanoma susceptibility.
|
25838620 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data show that this nonapeptide is a new tool that could be used to generate melanoma-specific T cells for adoptive immunotherapy or serve as a peptide vaccine for HLA-B*4002 melanoma patients.
|
18612636 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403.
|
17096150 |
2007 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, although an association with HLA-A, HLA-B, HLA-DRB1, or HLA-DQB1 was not demonstrated, the study of the HLA-C locus revealed that the analysis of the dimorphism at position 80 in the alpha1 helix may help to evaluate the risk and prognosis of melanoma in our population.
|
16365741 |
2006 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified three previously unknown peptides processed from melanosomal proteins tyrosinase (presented by HLA-A(*)2601 and -B(*)3801) and gp100 (presented by HLA-B(*)07021) and five neoantigens generated by somatic point mutations in the patient's melanoma.
|
16247014 |
2005 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As HLA-B35 is one of the most frequent HLA-B alleles, being present in 20% of the Caucasian individuals, this peptide may be a good target for peptide-based immunotherapy of melanoma.
|
15713214 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometric analyses identified a significantly (p < 0.01) lower expression of HLA-B antigens on melanoma cell cultures but not on autologous PBMC.
|
11251973 |
2001 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To identify regulatory sequences involved in locus-specific HLA class I gene transcription, a series of truncated HLA-A2 and HLA-B7 promoter-reporter constructs were transfected into melanoma cell lines expressing high and low levels of endogenous HLA-B, but comparable levels of HLA-A.
|
11132148 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The M88.7 T cell clone recognizes an antigen presented by HLA B*1302 on the melanoma cell line M88.
|
10790436 |
2000 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we show that novel sequences located 13 to 33 bp downstream of the transcription-initiation site mediate HLA-B locus-specific down-regulation in human melanoma cell lines.
|
9935159 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To study the involvement of promoter elements in HLA-B locus-specific downregulation, a series of reporter constructs containing 5'-flanking sequences of the HLA-A2 and -B7 genes were transfected into melanoma cell lines expressing high and low levels of HLA-B antigens.
|
10079292 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As HLA-B35 is one of the most frequent HLA-B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide-based immunotherapy of melanoma.
|
10597191 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peripheral blood lymphocytes isolated from a melanoma patient were stimulated in vitro with the autologous HLA-negative melanoma line transfected with autologous HLA B*3701 molecule.
|
10363990 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Total loss of HLA class I Ag expression was not noted; instead, two relatively common phenomena were identified: 1) A variable degree of expression of HLA-B Ags by melanoma cell lines and melanocytes; however, HLA-A Ags were consistently expressed in all cell types.
|
8027550 |
1994 |